Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
inSEIT AG is an early-stage Swiss biotech/CRO focused on enzyme immobilization technologies. The company leverages bioinformatics and AI-driven tools to develop tailored immobilized biocatalysts that improve efficiency and sustainability in chemical synthesis. Their SEITzyme catalogue offers ready-to-use immobilized enzymes optimized for various industrial applications. They have demonstrated the ability to reduce development time, cost, and risk associated with enzyme-based processes but do not report clinical results as they are a platform/service provider rather than a drug developer
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on inSEIT AG.